Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
Follow-Up Questions
Who is the CEO of Belite Bio Inc?
Dr. Yu-Hsin Lin is the Chairman of the Board of Belite Bio Inc, joining the firm since 2021.
What is the price performance of BLTE stock?
The current price of BLTE is $111.19, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Belite Bio Inc?
Belite Bio Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Belite Bio Inc market cap?
Belite Bio Inc's current market cap is $3.6B
Is Belite Bio Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Belite Bio Inc, including 3 strong buy, 7 buy, 1 hold, 0 sell, and 3 strong sell
